Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations-Reference-Cited by-同舟云学术

Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations

Published:2012-08 Issue:4 Volume:22 Page:246-254
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

Alton Eric W.¹,Boushey Homer A.²,Garn Holger³,Green Francis H.⁴,Hodges Michael⁵,Martin Richard J.⁶,Murdoch Robert D.⁷,Renz Harald⁸,Shrewsbury Stephen B.⁹,Seguin Rosanne¹⁰,Johnson Graham⁹,Parry Joel D.¹¹,Tepper Jeff¹²,Renzi Paolo¹³,Cavagnaro Joy¹⁴,Ferrari Nicolay¹⁰

Affiliation:

1. Imperial College, London, United Kingdom.

2. University of California, San Francisco, California.

3. Sterna Biologicals, Marburg, Germany.

4. University of Calgary, Calgary, Alberta, Canada.

5. Altair Therapeutics, San Diego, California.

6. National Jewish Health, Denver, Colorado.

7. Respiratory Discovery, GlaxoSmithKline R&D, Ware, United Kingdom.

8. Phillips University, Marburg, Germany.

9. AVI BioPharma Inc., Bothell, Washington.

10. Topigen Pharmaceuticals Inc., part of the Pharmaxis Ltd. Group, Montréal, Quebec, Canada.

11. Safety Assessment, GlaxoSmithKline R&D, Ware, United Kingdom.